During Wednesday’s Current trade, Shares of Marriott International Inc (NASDAQ:MAR), lost -1.10% to $74.61.
Marriott International Inc (MAR) the world’s favorite travel company, and Universal Music Group (UMG), the global music leader, have created a first-of-its-kind global marketing partnership that will comprise exclusive performances by established and emerging recording artists, branded video series, social content, music downloads, ticket offers and more. The partnership joins Marriott International’s 19 brands, counting The Ritz-Carlton, EDITION, JW Marriott, Renaissance and Marriott Hotels, with illustrious UMG music labels such as Capitol Music Group, Def Jam Recordings, Interscope Geffen A&M, Island Records, Republic Records and UMG Nashville.
Marriott and UMG are setting out to engage a new generation of experience-seekers, travelers and music fans to deliver unique #WithTheBand experiences. Starting this summer, the partnership will premiere live performances for hotel guests at select properties across Marriott International’s portfolio of brands around the globe. On June 30, 2015, the St. Pancras Renaissance London Hotel will feature a live performance by pop sensation and ‘The Voice Australia’ judge, Jessie J, kicking off a series of exclusive, on-property performances on five different continents.
Marriott International, Inc. operates, franchises, and licenses hotels and timeshare properties worldwide. It operates through three segments: North American Full-Service, North American Limited-Service, and International. The company also licenses the development, operation, marketing, sale, and administration of vacation ownership and related products under the Marriott Vacation Club, Grand Residences by Marriott, The Ritz-Carlton Destination Club, and The Ritz-Carlton Residences brands to the Marriott Vacations Worldwide Corporation.
Shares of Express Scripts Holding Company (NASDAQ:ESRX), declined -0.93% to $88.00, during its current trading session.
Express Scripts Holding Company (ESRX) declared its intention to release its second quarter earnings on Tuesday, July 28, 2015 after the market closes and will hold its quarterly conference call to talk about second quarter results on Wednesday, July 29, 2015, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time).
Express Scripts Holding Company operates as a pharmacy benefit administration (PBM) company in the United States and Canada. The company operates through two segments, PBM and Other Business Operations. The company’s PBM segment’s services comprise clinical solutions to enhance health outcomes, such as adherence, case coordination, and personalized medicine; specialized pharmacy care; home delivery pharmacy; specialty pharmacy, counting the distribution of fertility pharmaceuticals that require special handling or packaging; and retail network pharmacy administration.
Akorn, Inc. (NASDAQ:AKRX), during its Wednesday’s current trading session decreased -1.62% to $41.85.
Akorn, Inc. (AKRX), a leading specialty pharmaceutical company, declared that it has launched Acetylcysteine Injection 6 g/30 mL in 30 mL single-dose vials. The launch follows an approval of an abbreviated new drug application (ANDA) for the product from the U.S. Food and Drug Administration (FDA) on March 24, 2015. Akorn’s product is therapeutically equivalent to Acetadote(R) injection marketed by Cumberland Pharmaceuticals Inc.
Akorn, Inc. develops, manufactures, and markets generic and branded prescription pharmaceuticals, in addition to animal and over-the-counter (OTC) consumer health products in the United States and internationally. It operates through two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment markets generic and branded ophthalmics, injectables, oral liquids, otics, topical, inhalants, and nasal sprays. This segments generic products comprise Clobetasol Propionate, a corticosteroid, which is used to treat various skin conditions; Fluticasone Propionate, a corticosteroid used for nasal symptoms of allergic and non-allergic rhinitis conditions; Lidocaine/Prilocaine, a topical anesthetic; Progesterone, which is used to prevent endometrial hyperplasia; Vancomycin, an antibiotic used to treat bacterial infections; and other products. T
Finally, UDR, Inc. (NYSE:UDR), decreased -0.13%, to $33.06.
UDR, Inc. (UDR) declared that it will release its second quarter 2015 financial results on Monday, July 27, 2015 after the market closes. A conference call will be held on Tuesday, July 28, 2015 at 1:00 p.m. Eastern time. The conference call will be open to the public.
UDR, Inc. is an independent real estate investment trust. The firm invests in the real estate markets of the United States. It owns, operates, acquires, renovates, develops, redevelops, and manages multifamily apartment communities. The firm was formerly known as United Dominion Realty Trust, Inc. UDR, Inc. was founded in 1972 and is headquartered in Denver, Colorado with additional offices in Dallas, Texas; Houston, Texas; Newport Beach, California; Orlando, Florida; Phoenix, Arizona; Santa Clara, California; Tampa, Florida; and Washington DC, Virginia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
